2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 469

Window of Opportunity to Achieve Major Outcomes in Early Rheumatoid Arthritis Patients: How Persistence with Therapy Matters

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 872

Work Limitations and Disability in Patients with Systemic Vasculitis

Vasculitis Poster I

9:00AM-11:00AM: Abstract Number: 102

Xanthine Oxidase Gene Variants and Their Association with Blood Pressure and Incident Hypertension: A Population Based Study

Genetics, Genomics and Proteomics Poster I

11:00AM-12:30PM: Abstract Number: 900

A Multidimensional Immunomics Approach Annotates an Immunome Shaped By the Interplay Between the Periphery and the Skin Microenvironment in Systemic Sclerosis

ACR Plenary Session I: Discovery 2015

11:00AM-12:30PM: Abstract Number: 898

A Randomized Double-Blind Study of Denosumab Compared with Zoledronic Acid in Postmenopausal Women with Osteoporosis Previously Treated with Oral Bisphosphonate

ACR Plenary Session I: Discovery 2015

11:00AM-12:30PM: Abstract Number: 899

HA20: A Novel Autoinflammatory Disease Caused By Haploinsufficiency of A20, Encoded By TNFAIP3

ACR Plenary Session I: Discovery 2015

11:00AM-12:30PM: Abstract Number: 896

Herpes Zoster and the Short Term Risk for Ischemic Stroke in Patients with Autoimmune Diseases

ACR Plenary Session I: Discovery 2015

11:00AM-12:30PM: Abstract Number: 897

Intra-Articular Corticosteroids Are Safe and Have No Major Effect on Structural Progression of Synovitic Knee OA: A 2-Year Randomized Controlled Trial of 3-Monthly Triamcinolone Hexacetonide

ACR Plenary Session I: Discovery 2015

2:30PM-4:00PM: Abstract Number: 913

A Comparison of Physician Based and Patient Based Criteria for the Diagnosis of Fibromyalgia

Fibromyalgia: Insights Into Diagnostic Criteria and Symptom Epidemiology

2:30PM-4:00PM: Abstract Number: 972

A Phase 2b Study Evaluating the Efficacy and Safety of Subcutaneously Administered Tregalizumab in Subjects with Active Rheumatoid Arthritis (RA) Despite Treatment with Methotrexate (MTX)

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy I: Biologics

2:30PM-4:00PM: Abstract Number: 998

A Psychometric Analysis of the Social Interaction Anxiety Scale (SIAS-6) in Systemic Sclerosis: Results from the Scleroderma Patient-Centered Intervention Network (SPIN) Cohort

ARHP I: Exemplary Abstracts

2:30PM-4:00PM: Abstract Number: 977

A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naïve to Biologic Disease Modifying Anti-Rheumatic Drugs with Active Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Treatment of AS

2:30PM-4:00PM: Abstract Number: 944

Activity of Type I and Type II Interferons in Dermatomyositis Skin Is Correlated with Characteristic Pathologic Features

Muscle Biology, Myositis and Myopathies I

2:30PM-4:00PM: Abstract Number: 1002

Aiming for Remission in Early RA: Impact on Pain during the First Year of Treatment

ARHP I: Exemplary Abstracts

2:30PM-4:00PM: Abstract Number: 961

Altered Th Cell Plasticity Favors Th17 Cells in Rheumatoid Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].